AN2 Therapeutics, Inc.宣布,正式启动针对脓肿分枝杆菌复合体肺病的2期研究者发起临床试验,该试验将评估其在研药物Epetraborole的疗效与安全性。
AN2 Therapeutics, Inc.宣布,正式启动针对脓肿分枝杆菌复合体肺病的2期研究者发起临床试验,该试验将评估其在研药物Epetraborole的疗效与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.